anchor.diff:               treating institution's identity is provided in order to ensure that the current
                (within 365 days) date of institutional review board approval for this study has been
                entered in the system
  -      ",1476145970,,,,,,,,,,,,,,,,,,,,,,,,,,
  +      "
   NCT02635009,Phase 2/Phase 3,NRG Oncology,Other,Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer,1,18,150,,,,include,,,,,include,include,,,,,,,,,,,,,,,"
           Inclusion Criteria:
   
  
positive.code:           -  Women who are pregnant, plan to become pregnant, and/or breastfeed during the study.
  
          Other protocol defined inclusion/exclusion criteria could apply
        ",1476145970,,,,,,,,,,,,,,,,,,,,,,,,,,
  NCT02200757,Phase 2,CytRx,Industry,"A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy",1,18,150,,,,include,,,,,include,include,,require,,,,,,,,,,,,,"
          Inclusion Criteria:
  
            1. Age â‰¥18 years male or female.
  
            2. Histological confirmation of SCLC.
  
  
negative.code:         second- or third-line of treatment for advanced disease.
  
          5. No other current active malignancy requiring anticancer therapy. 6. Radiographically
          documented measurable disease (defined by the presence of  1 radiographically documented
          measurable lesion).
  
          7. One prior platinum-containing chemotherapy for metastatic or recurrent NSCLC unless
          patients are ineligible to receive it. Patients may have received no more than one line of
          chemotherapy; immunotherapy in prior line of treatment (first or second line) is allowed.
          Absolute neutrophil count (ANC)  1500 cells/mm3.
  
          8. Platelets  100,000 cells/mm3. 9. Hemoglobin (Hgb)  9 g/dL. 10. Aspartate transaminase
          (AST/serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (ALT/serum
          glutamic pyruvic transaminase [SGPT]) _ 2.5  upper limit of normal range (ULN) or _ 5.0 
          ULN if liver metastases.
  
          11. Total bilirubin _ 1.5 ULN (unless there is a known history of Gilberts Syndrome).
  
          12. Serum creatinine _ 1.5 x ULN, or calculated creatinine clearance  60 mL/min (if renal
          impairment is suspected 24-hour urine collection for measurement is required).
  
          13. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 14. Eastern
  